Investors and industry observers can follow the company's update via a live audio webcast hosted on the BioMarin investor relations portal. Following the event, the company plans to maintain an archived version of the session on its website for a limited duration.

Founded in 1997, BioMarin currently manages a portfolio of nine commercial therapies. The firm focuses on developing medicines for genetically defined conditions, leveraging its research pipeline to transition clinical and preclinical candidates into market-ready treatments.